Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Bevacizumab + HSRT vs Bevacizumab in Recurrent Glioblastoma
NCT05611645Phase 2Active, not recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by Huashan Hospital. Started Oct 2022; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05611645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611645.